RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness.

Trial Profile

RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2015

At a glance

  • Drugs RI 002 (Primary)
  • Indications Immunological disorders; Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Sponsors ADMA Biologics
  • Most Recent Events

    • 21 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Feb 2010 Planned end date changed from 1 May 2009 to 1 May 2010 as reported by ClinicalTrials.gov.
    • 10 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top